Pediatric Infection and Vaccine

The Korean Society of Pediatric Infectious Diseases (대한소아감염학회)
권호 표지

Severe Pneumonia Caused by 2009 Pandemic Influenza A (H1N1) Virus in Children and Corticosteroid Treatment

소아에서 2009 신종 인플루엔자 A (H1N1) 중증 폐렴과 스테로이드 치료

  • Sohn, Yu Rak (Department of Pediatrics, Daegu Fatima Hospital) ;
  • Kim, Jong Hee (Department of Pediatrics, Daegu Fatima Hospital) ;
  • Ma, Sang Hyuk (Department of Pediatrics, Changwon Fatima Hospital) ;
  • Lee, Kyung Yil (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Kang, Jin Han (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
  • 손유락 (대구파티마병원 소아과학교실) ;
  • 김종희 (대구파티마병원 소아과학교실) ;
  • 마상혁 (창원파티마병원 소아과학교실) ;
  • 이경일 (가톨릭대학교 의과대학 소아과학교실) ;
  • 강진한 (가톨릭대학교 의과대학 소아과학교실)
  • Received : 2011.10.01
  • Accepted : 2011.10.17
  • Published : 2011.12.25
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : The effect of corticosteroid on severe pneumonia caused by 2009 pandemic influenza (H1N1) A virus is controversial. This study was aimed to present the effects of early, short-term corticosteroid treatment for severe pneumonia with this virus infection. Methods : A retrospective analysis was performed on severe pneumonia patients (37 patients) who had severe respiratory distress at presentation requiring oxygen therapy and received intravenous methylprednisolone (MP, 8-10 mg/kg, divided in 4 doses/day for 2-3 days) with oseltamivir. The clinical and laboratory characteristics of the patients were evaluated through the medical records and chest radiographic findings. Results : The mean age and male-to-female ratio of the patients were 6.5${\pm}$2.9 years of age, and 3.4:1 (male 29 patients), respectively. The 5-9 aged group was predominant among the age groups (25 patients, 67.6%). Duration of fever prior to admission was 1.4${\pm}$0.6 days and dyspnea developed within 24 h after beginning of respiratory symptoms in all patients. All patients were previously healthy and received oseltamivir within 48 h. Thirteen patients (35.1%) developed dyspnea during oseltamivir treatment. Following MP infusion, all 37 patients including 13 progressive pneumonia patients during oseltamivir treatment showed an immediate halt in the progression of pneumonic infiltration with rapid clinical improvement. There were no side-effects following steroid use. Conclusion : For severe pneumonia patients, early corticosteroid treatment halted clinical exacerbation, and possibly prevented progression to acute respiratory distress syndrome. Further controlled clinical studies are needed for the role of corticosteroids and antivirals on severely affected patients with influenza virus infections.

목 적: 2009년에 신종 인플루엔자 바이러스에 감염이 되어 본원에 입원한 폐렴 환자들 중 호흡곤란을 보여 중증 폐렴으로 진행한 환자에서 조기에 스테로이드 치료를 하였던 37명의 임상적 특성, 검사실 소견, 치료결과를 보고하고자 한다. 방 법: 2009년 10월 1일부터 12월 31일까지 창원 파티마병원에 기침과 발열 등으로 입원한 환자 중 입원시 및 입원 중 호흡곤란을 보여 조기 스테로이드 치료를 받은 환자 37명을 대상으로 하였다. 환자들은 모두 방사선 검사에서 폐렴이 확인되었고, 신종 인플루엔자 진단을 위하여 실시간 역전사효소 중합반응(RT-PCR) 검사와 신속항원검사를 받았으며, 모두 RT-PCR에서 양성을 보였다. 대상 환자들의 의무기록과 방사선 소견을 후향적으로 분석하였다. 결 과:대상 환자 37명의 평균 연령은 $6.5{\pm}2.9$세(2-16세)이었고, 남아 29명, 여아 8명(남녀비=3.4:1)이었다. 입원 전 평균 발열일은 $1.4{\pm}0.6$일(4시간-3일)이었으며, 발열과 기침을 보인 후 호흡곤란이 발생하기까지 걸린 시간이 평균 $9.6{\pm}3.5$시간(1-24시간)이었다. 대상환자 37명중 13명(35.1%)은 항바이러스제(oseltamivir)를 투여 받는 중 호흡곤란이 심해져서 스테로이드 치료를 받았다. 스테로이드 치료로는 모든 환자에 대해 정맥용 메틸프레드니솔론을 체중(kg) 당 8-10 mg/일 용량으로 하루에 4회 나누어 정맥으로 투여하였고, 호흡곤란이 없어진 후 바로 스테로이드 투여를 중지하였다. 평균 투여일은 $1.9{\pm}0.5$일(1-3일)이었다. 모든 환자들이 합병증 없이 퇴원하였으며 퇴원 후 폐렴의 후유증으로 재입원한 환자는 없었다. 결 론 : 신종 인플루엔자 바이러스 폐렴 환자들의 일부는 발병 초기에 호흡곤란을 보이는 중증 폐렴으로 빠르게 진행하였고 조기 스테로이드 치료가 임상적 증상 및 방사선 소견의 빠른 호전을 가져왔다. 따라서 향후 스테로이드제 및 항바이러스제의 중증 폐렴 환자에 대한 효과 판정을 위한 전향적 대조 임상 연구가 필요하다.

Keywords

References

  1. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009;459:931-9. https://doi.org/10.1038/nature08157
  2. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605-15. https://doi.org/10.1056/NEJMoa0903810
  3. World Health Organization [homepage on the Internet]. Geneva, Switzerland: WHO c2009 [updated 2009 June 11 cited 2009 July 17]. Global Alert and Response; [about 2 screens]. Available from: http://www.who.int/csr/diseea/swineflu/frequently_asked_questions/levels_pandemic_alert/en/index.html
  4. Kim WJ. Novel influenza A/H1N1 pandemic: current status and prospects J Korean Med Assoc 2009;52:787-94. https://doi.org/10.5124/jkma.2009.52.8.787
  5. Korean Center for Disease Control. Epidemiology of early detected Novel Influenza A (H1N1) in Korea, 2009. Public Health Wkly Rep 2009;2:689-91.
  6. Lee HJ, Min SJ, Choi JW, Kang EK. Clinical characteristics of hospitalized pediatric patients with 2009 novel influenza A infection. Pediatr Allergy Respir Dis 2010;30:130-7.
  7. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010;362:1708-19. https://doi.org/10.1056/NEJMra1000449
  8. Falagas ME, Vouloumanou EK, Baskouta E, Rafailidis PI, Polyzos K, Rello J. Treatment options for 2009 H1N1 influenza: evaluation of the published evidence. Intern J Antimicrob Agents 2010;35:421-30. https://doi.org/10.1016/j.ijantimicag.2010.01.006
  9. Reddy D. Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir. J Antimicrob Chemother 2010 Apr;65(Suppl 2):ii35-ii40.
  10. de Jong MD, Simmons CP, Thanh TT, Hien VH, Smith GJ, Chau TN, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006;12:1203-7. https://doi.org/10.1038/nm1477
  11. Eichelberger MC. The cotton rat as a model to study influenza pathogenesis and immunity. Viral Immunol 2007;20:243-9. https://doi.org/10.1089/vim.2007.0017
  12. La Gruta NL, Kedzierska K, Stambas J, Doherty PC. A question of self-reservation: immunopathology in influenza virus infection. Immunol Cell Biology 2007;85:85-92. https://doi.org/10.1038/sj.icb.7100026
  13. To KK, Hung IF, Li IW, Lee KL, Koo CK, Yan WW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010;50:850-9. https://doi.org/10.1086/650581
  14. Lee KY, Rhim JW, Kang JH. Hyperimmune cells (T cells) may be responsible for acute lung injury in influenza virus infections: a need for early immune-modulators for severe cases. Med Hypotheses 2011;76:64-9. https://doi.org/10.1016/j.mehy.2010.08.032
  15. Quispe-Laime AM, Bracco JD, Barberio PA, Campagne CG, Rolfo VE, Umberger R, et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med 2010;36:33-41. https://doi.org/10.1007/s00134-009-1727-6
  16. Linko R, Pettila V, Ruokonen E, Varpula T, Sari Karlsson S, Tenhunen J, et al. FINN H1N1-study group. Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A (H1N1) infection in Finland. Acta Anesth Scand (In press).
  17. Confalonieri M, Cifaldi R, Dreas L, Viviani M, Biolo M, Gabrielli M. Methylprednisolone infusion for lifethreatening H1N1-virus infection. Ther Adv Respir Dis 2010;4:233-7. https://doi.org/10.1177/1753465810376951
  18. Roberts C, Nirmalan M, O'Shea S. Steroid-sensitive post-viral inflammatory pneumonitis (PVIP). Am J Respir Crit Care Med 2010;182:1089-90.
  19. Kil HR, Lee JH, Lee KY, Rhim JW, Youn YS, Kang JH. Early corticosteroid treatment for severe pneumonia caused by 2009 H1N1 influenza virus. Critical Care 2011;15:413. https://doi.org/10.1186/cc10082
  20. Annane D. Pro: The illegitimate crusade against corticosteroids for severe H1N1 pneumonia. Am J Respir Crit Care Med 2011;183:1125-6. https://doi.org/10.1164/rccm.201102-0345ED
  21. Rhim JW, Lee KY, Youn YS, Kang JH, Kim JC. Epidemiological and clinical characteristics of childhood pandemic 2009 H1N1 virus infection: An observational cohort study. BMC infect Dis 2011;11:225. https://doi.org/10.1186/1471-2334-11-225
  22. Bettinger JA, Sauve LJ, Scheifele DW, Moore D, Vaudry W, Tran D, et al. Pandemic influenza in Canadian children: a summary of hospitalized pediatric cases. Vaccine 2010;28:3180-4. https://doi.org/10.1016/j.vaccine.2010.02.044
  23. Matthay MA, Lia KD. Con: Corticosteroids are not indicated for treatment of acute lung injury from H1N1 viral pneumonia. Am J Respir Crit Care Med 2011;183:1127-8. https://doi.org/10.1164/rccm.201103-0395ED
  24. Kim SH, Hong SB, Yun SC, Choi WI, Ahn JJ, Lee YJ. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011;183:1207-14. https://doi.org/10.1164/rccm.201101-0110OC
  25. Brun-Buisson C, Richard JC, Mercat A, Thiebaut A, Brochard L. Early corticosteroids in severe Influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011;183:1200-6. https://doi.org/10.1164/rccm.201101-0135OC
  26. Witkop CT, Duffy MR, Macias EA, Gibbons TF, Escobar JD, Burwell KN, et al. Novel influenza A (H1N1) outbreak at the US Air Force Academy: epidemiology and viral shedding duration. Am J Prev Med 2010;38:121-6. https://doi.org/10.1016/j.amepre.2009.10.005
  27. Confalonieri M, D'Agaro P, Campello C. Corticosteroids do not cause harmful increase of viral load in severe H1N1 virus infection. Intensive Care Med 2010;36:1780-1. https://doi.org/10.1007/s00134-010-1964-8
  28. Aviram G, Bar-Shai A, Sosna J, Rogowski O, Rosen G, Weinstein I, et al. H1N1 influenza: initial chest radiographic findings in helping predict patient outcome. Radiology 2010;255:252-9. https://doi.org/10.1148/radiol.10092240
  29. Choi SH, Kang EY, Kim JS, Kim YK. Radiologic review of an outbreak of the pandemic (H1N1) 2009 Virus Infection at a university hospital in Seoul, Korea. J Korean Soc Radiol 2011;64:341-50. https://doi.org/10.3348/jksr.2011.64.4.341
  30. Korppi M, Don M, Valent F, Calciani M. The value of clinical features in differentiating between viral, pneumococcal and atypical bacterial pneumonia in children. Acta Pediatr 2008;97:943-7. https://doi.org/10.1111/j.1651-2227.2008.00789.x
  31. World Health Organization: Human infection with new influenza A (H1N1) virus: Clinical observations from a school associated outbreak in Kobe, Japan, May 2009. Wkly Epidemiol Rec 2009;84:237-48.
  32. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009;361:1935-44. https://doi.org/10.1056/NEJMoa0906695
  33. Tang BM, Craig JC, Eslick GD, Seppelt I, McLean AS. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: A systemic review and meta-analysis. Crit Care Med 2009;37:1594-603. https://doi.org/10.1097/CCM.0b013e31819fb507